Ceritinib Aggravates Glycemic Control in Insulin-treated Patients with Diabetes and Metastatic ALK-positive Lung Cancer
Ceritinib Aggravates Glycemic Control in Insulin-treated Patients with Diabetes and Metastatic ALK-positive Lung Cancer
复制标题
DOI：
10.2169/internalmedicine.1870-18
复制
发表时间：
2019-01-01
影响因子：
1.2
通讯作者：
Tanaka, Tomoaki
中科院分区：
文献类型：
--
作者：
Sakuma, Ikki;Nagano, Hidekazu;Tanaka, Tomoaki
我们在此报告了一名 75 岁女性，她患有胰岛素治疗的糖尿病和转移性间变性淋巴瘤激酶 (ALK) 重排非小细胞肺癌，她接受第二代 ALK 抑制剂色瑞替尼治疗后，肿瘤显着缩小。然而，她的空腹血糖升高，特别是在服用色瑞替尼后的前两周，甚至增加胰岛素总剂量也没有恢复正常。停用色瑞替尼后，她的血糖水平迅速下降。由于色瑞替尼对胰岛素受体的抑制作用，可能会加重缺乏代偿性胰岛素分泌的糖尿病患者的高血糖。应仔细监测色瑞替尼引起的高血糖，特别是在色瑞替尼给药后的前两周。
We herein report a 75-year-old woman with insulin-treated diabetes and metastatic anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer who received ceritinib, a second-generation ALK inhibitor, and achieved dramatic tumor reduction. However, her fasting blood glucose increased, particularly markedly in the first two weeks after ceritinib administration, and did not normalize even increasing the total insulin dose. After discontinuing ceritinib, her glucose levels rapidly reduced. Ceritinib can aggravate hyperglycemia in patients with diabetes who lack compensatory insulin secretion, due to its inhibitory effects on the insulin receptor. Careful monitoring for ceritinib-induced hyperglycemia should be performed, especially in the first two weeks after ceritinib administration.